©The Author(s) 2025.
World J Gastrointest Surg. Nov 27, 2025; 17(11): 112557
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.112557
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.112557
Table 6 Odds ratio of surgical site infection occurrence in colon group and rectum group (logistic model), n (%)
| SSI | |
| RS-Rb (n = 17) | 6 (35.3) |
| C-S (n = 18) | 1 (5.6) |
| Odds ratio | 9.273 |
| 95%CI | 0.979-87.870 |
| P value | 0.0522 |
| Ra-Rb (n = 12) | 5 (41.7) |
| C-RS (n = 23) | 2 (8.7) |
| Odds ratio | 7.498 |
| 95%CI | 1.180-47.660 |
| P value | 0.0328 |
- Citation: Shinji S, Yamada T, Matsuda A, Uehara K, Yokoyama Y, Takahashi G, Iwai T, Miyasaka T, Kanaka S, Hayashi K, Yoshida H. Clinical utility of a novel concentrated enteral formula in patients undergoing colorectal cancer surgery: A randomized controlled trial. World J Gastrointest Surg 2025; 17(11): 112557
- URL: https://www.wjgnet.com/1948-9366/full/v17/i11/112557.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i11.112557